David A. Siegel Arcus Biosciences, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 295,800 shares of RCUS stock, worth $4.91 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
295,800
Previous 124,100
138.36%
Holding current value
$4.91 Million
Previous $974,000
147.13%
% of portfolio
0.01%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding RCUS
# of Institutions
209Shares Held
67MCall Options Held
3.18MPut Options Held
167K-
Black Rock Inc. New York, NY9.76MShares$162 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.56MShares$109 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.97MShares$99 Million0.11% of portfolio
-
Woodline Partners LP San Francisco, CA4MShares$66.4 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$61.2 Million1.03% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.2B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...